macs monthly header with macs logo and graphic of medical professionals in training

The latest in substance use disorders and pain management education for healthcare providers

 

October 2026

Greetings,


Welcome to the October edition of the MACS Monthly newsletter!


Recent federal legislation has brought significant changes to Medicaid eligibility that may affect patients in Maryland. Changes for some non-citizens take effect October 2026, with work requirements and more frequent renewal timelines for certain adults beginning January 2027. Providers are encouraged to stay informed and help patients understand how these changes may affect their coverage. Visit the Maryland Department of Health's Medicaid changes page for the latest information and resources.


October also brings American Pharmacists Month, a dedicated time to honor the contributions of pharmacists and pharmacy technicians to patient health and safety. Pharmacy professionals are uniquely positioned to support overdose prevention and expand access.


At MACS, pharmacists are an integral part of our interdisciplinary team of addiction medicine specialists. They work directly with providers to answer clinical questions about evidence-based dosing, harm reduction tools and a range of patient-related concerns. This month, we celebrate the pharmacy professionals who show up every day for patients living with SUDs and chronic pain.


Providers, including pharmacists, can access support in caring for patients with SUDs and chronic pain by scheduling an individualized consultation or registering for an upcoming training with the MACS team of addiction medicine specialists. Call 1-855-337-MACS (6227), email macs@som.umaryland.edu or visit www.marylandmacs.org to learn more.


Explore this newsletter and the tools available on the MACS website for additional information about provider education and treatment resources.


– The MACS Team

 

OCTOBER 24: NATIONAL PRESCRIPTION DRUG TAKE BACK DAY

National Prescription Drug Take Back Day is on Saturday, October 24. In addition to finding nearby collection sites, help your patients safely dispose of unused medications from home by requesting free, easy-to-use Deterra drug disposal pouches from MACS.


Please note that this form is for healthcare providers only and should be used to order pouches for their practices and organizations.

 

UPDATED FACT SHEET

We have updated our Xylazine and Opioid Use fact sheet to reflect critical new clinical and administrative guidance for Maryland prescribers and healthcare teams.

 

Our updated fact sheet highlights new ICD-10-CM diagnostic codes (T65.841–T65.844) designed to support providers in seeking reimbursement for treating xylazine-related harms while helping track the prevalence of xylazine. Please utilize the new codes when treating xylazine wounds.

 

EDUCATION

Upcoming MACS Training Opportunities

 

MACS Webinar

Substance Use Disorders in Older Adults


Thursday, October 22 | 12:00 – 1:00 p.m. ET


Presented by MACS Consultant Michael Fingerhood, MD

MACS Webinar

Community-Based Treatment for Opioid Use Disorder: Models, Access, and the Path Forward


Monday, December 7 | 12:00 – 1:00 p.m. ET


Presented by Will Garneau, MD, MPH, MHS, Assistant Professor, Johns Hopkins University School of Medicine

Upcoming Trainings of Interest

Grayken Center for Addiction Training & Technical Assistance

Between the Leaves: Prevalence, Withdrawal and Approaches to Care for Kratom Use


Thursday, October 8 | 3 – 4 p.m. ET

NAADAC, the Association for Addiction Professionals

The Battle at Home: Exploring the Complexities of PTSD, Substance Misuse, and Other Co-Occurring Conditions in the African American Veteran Population


Wednesday, October 14 | 12 – 1:30 p.m. ET

Yale Program in Addiction Medicine

Novel Approaches to Buprenorphine Extended-Release and Methadone Initiation and Alpha-2 Agonist Withdrawal Management


Tuesday, October 27 | 12 – 1 p.m. ET

 

MACS ECHO Sessions

Join our learning communities for continuous case-based discussions and didactic presentations linking expert specialist teams with healthcare providers and their practices. MACS ECHO sessions count toward the required 8-hours of SUD training for DEA license renewal or registration.

Opioid Treatment Program

Kratom: Clinical Perspectives for Addiction Professionals


Aaron Greenblatt, MD


Wednesday, October 7

12:30 – 1:30 p.m.

Maternal Health

Counseling on Prenatal Cannabis Use


Nishant Shah, MD, MPH, and Tina Suliman, MSPH


Tuesday, October 13

12 – 1 p.m.

Substance Use Care for the General Practitioner

Nurse Practitioners Advancing Substance Use Disorder Care in Maryland: Quality, Innovation and Advocacy


Marian Currens, CRNP


Wednesday, October 21

12:30 – 1:30 p.m.

Peer Recovery Specialists

Science Over Stigma: The Role of Medications for Opioid Use Disorder in Recovery


Devang Gandhi, MD


Monday, November 2

12:30 – 1:30 p.m.

 

CONFERENCES & EVENTS

2026 Maryland Society of Health-System Pharmacy Fall Seminar

Friday, October 16

Marriott Owings Mills Metro Centre | Owings Mills, Maryland

MACS exhibit table

2026 Maryland Rural Health Conference

Monday, October 19

Hilton Baltimore BWI Airport | Linthicum Heights, Maryland

MACS exhibit table

 

POST OVERDOSE OUTREACH SURVEY

Does your organization conduct post overdose outreach? If so, the Office of Overdose Prevention and Education requests your response to the survey described and linked below.


The purpose of this survey is to gather information about post overdose outreach in Maryland. The information gathered about Maryland’s programs will help the Office of Overdose Prevention and Education to plan and implement organizational and programmatic support for post overdose outreach activities in the state.


The survey will close on Friday, October 16.


If you have any questions, please contact the Non Fatal Overdose Program Coordinator at harriet.smith1@maryland.gov.

 

NEWS

Abandonment of Prescribed Buprenorphine for Opioid Use Disorder, 2020-2024


A new study found that abandonment of first buprenorphine prescriptions for opioid use disorder nearly doubled between 2020 and 2024, rising from 19% to 37%. Patients who did not fill their prescriptions were more likely to be younger (54 versus 57 years), Hispanic, commercially insured and facing higher pharmacy deductibles. Even as policy changes have worked to expand access to this lifesaving medication, these findings show a persistent gap between prescribing and treatment initiation. Strengthening linkage to care and addressing pharmacy-level barriers remain critical to closing that gap.


Read more...

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment



 A new target trial emulation study compared the effectiveness of buprenorphine-naloxone versus extended-release (XR) naltrexone following medically managed opioid withdrawal treatment. Initiating buprenorphine-naloxone after MMOW discharge was associated with a lower risk of nonfatal opioid overdose at 24 weeks than initiating XR naltrexone, but a similar risk of all-cause mortality. The findings reveal how medication selection impacts post-discharge nonfatal overdose rates and what it means for improving long-term MOUD retention.


Read more...

Mental Health Predictors of Treatment Engagement and Completion in Substance Use Disorder Treatment: Within- and Between-Person Evidence From a 15-Year Western Australian Cohort



A 15-year retrospective cohort study in Australia examined how mental health symptoms and clinical risks affect treatment engagement and completion. Using multilevel Bayesian structural equation models, the researchers separated individual baseline differences from episode-to-episode symptom fluctuations. Key findings reveal that elevated stress consistently reduced treatment attendance and completion rates. Conversely, transient increases in depressive symptoms paradoxically improved treatment attendance, while suicide risk decreased attendance but extended episode duration. Identifying and supporting clients during periods of high stress, alongside sustaining engagement for those with elevated suicide risk, could help improve overall treatment retention and completion.


Read more...

U.S. Drug Overdose Deaths that Occurred in Isolation, 2022–2024



An analysis of data from the State Unintentional Drug Overdose Reporting System spanning January 2022 through December 2024 reveals that 75.5 percent of the 191,577 unintentional or undetermined overdose deaths across 46 states and Washington, D.C., occurred in isolation. More than half of all these fatalities took place specifically within a house or apartment setting. Among those isolated home deaths, the majority had no evidence of a bystander present, while about one in five involved an intimate partner or family member who was nearby in the home but spatially separated. Because fast-acting synthetic opioids leave a narrow window for intervention, these findings highlight the urgent need to expand overdose education and naloxone distribution to household contacts, as well as leverage emerging phone and wearable technologies to protect individuals who use drugs alone.


Read more...

 

October Observances

American Pharmacists Month

Domestic Violence Awareness Month

National Latino Physician Day

October 1

National Midwifery Week

October 4 – 10

Physician Associate Week

October 6 – 12

World Mental Health Day

October 10

National Pharmacy Week

October 18 – 24

National Prescription Drug Take Back Day

October 24

Follow us to stay connected:

Facebook  LinkedIn  X  Instagram  YouTube
 

RESOURCES

Call for Poster Abstracts & Session Proposals (American Society of Addiction Medicine Annual Conference)

Medicaid Check-In (Maryland Health Connection)

Navigating Mental Health and Substance Use Care: An Introductory Guide for Families (Substance Abuse and Mental Health Services Administration)

 
X Share
LinkedIn Share
 

Follow us:

Facebook  X  LinkedIn  Instagram  YouTube